Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
What do mean “There is no ‘endpoint outcome’ measure.”
Of course there are and in the PDD it was a battery of tests not all reported on.
Hence the PDD trial was named a “Proof of concept” and precious little has happened with that indication since for now over years.
Yes as I said “at least” a year.
Ohsay if I recall originally got upset with me saying Anavex needed to publish convincing news to sustain the $AVXL share price higher. That was some years ago now and we still have more than year ahead of us to maybe finally get that kind of news.
The two possible events you mentioned won’t be that sustainable $AVXL price news needed.
Same place as we find you, otherwise what would you do?
What - not reporting on all endpoint outcome measures is not a trial fail?
Similar to the fact that not reporting ADL in P2b/3 trial per protocol is not agreeable with a 'met all endpoints' statement. As others have observed meeting all endpoints is not always a requirement for achieving regulatory approval, but it helps a lot!
Also look back to make sure you understood the context.
Well indeed.
There is securities class action case on the go, that's a bit of news we haven't seen in while.
The PDD trial was a proof of concept study that did not report on the full endpoint outcome measures.
One of several yes, and of course there will now be flurry of posts speculating that’s where the big news will finally drop.
There won’t be any big news for over a year and we won’t know if it will be good. That of course contingent on Anavex actually filing an MAA and having it validated maybe this year.
If it helps with your investment frustrations, you are welcome.
Relative to your own posts, maybe not so much.
Meant do NOT have the reference to hand.
Yes Complete non conditional approval. Do have the reference to hand.
Why did the article copy the Anavex company PR?
BioStock's AI thingy was rubbish.
Quite consistent with what I have said in the past. I find it increasingly difficult to see credibility in Missling.
Is he just really excited and genuine, but inexperienced or manipulative, untrustworthy and self centred acting as if genuine - I can’t make up my mind.
I have in past expressed my difficulty with deciding between TDG or Madoff, the suspicion is now Madoff more than ever.
The market is increasingly rejecting the EMA 85% chance of approval thesis.
Don't know when, but in principle yes.
Nice to see that Kathy Skoff of Anavex is updating clinicaltrials.gov. Perhaps going forward we can expect that Anavex keeps the information up to date and consistent with what the company does as says in other contexts.
The point though was that he was not there to stop Missling from declaring all
endpoints met.
Kun Jin is more than likely responsible for the much later “the trial was successful because” avenue.
Anavex have been planning to release a peer reviewed PDD trial data publication for over 3 years now.
Are you imaging integrity in Missling?
I like the confidence of inexperienced and hope you too are right.
Also 19 applications were withdrawn mostly because the applicant was unable to answered feedback and requests from the CHMP team at the process clock stops.
I would want to be the business advisor to anyone who’d want me as their advisor.
You must be one the make believe satisfied $AVXL investors clinging onto the 85% chance story.
I just think that as a ‘real’ $AVXL investor you are not very well up to speed on the facts.
Not a good rescue attempt either.
Well Kun Jin wasn't there to guard the Dec 1st 2022 met all endpoints bs!
Cause he can't admit failure.
You do realise, I hope, that with posts like that you are not supposed or even allowed to own $AVXL shares.
Delayed data releases are usually an indication that results are not that great.
A lot of those 'pages' are generated from databases of trial and other data points.
Most of those pages will never be read by any human, but AI should help regulators discover hidden issues that so far have often gone by,
Yes just a matter of for which outcome 😀
I still that I want see an MAA filed and accepted before deciding, if that doesn’t happen I think I am done.
Once a WGT member always must be biased, in the script I imagine.
At least it is not a P2/3 potential pivotal retail lure this time.
Another huge and meaningful trial that will give solid insights into Misslings modus operandi, if nothing else. And it splits that huge n between placebo and drug in two parts, so the results will be very malleable lending itself to all sorts of cool post hoc analysis and wonderful conclusions to carry on from.
Salary for years in the making here.
If you wait you can always buy $AVXL cheaper. Just ask damp powder boy,
Not quite sure what the contention is here, so I’ll agree with your point too.
Who is on the company's SAB or are employees of whatever reputation will have no baring on facts that can be established, which is what the case and court will be relying on.
One needs to add to that the time it will take Anavex to respond satisfactorily, which hopefully they can, to CHMP feedback and requests at the two process clock stops.
You'll be fine as there is absolute no problem with Anavex and Missling has got your back, WGT!!!